Transparency Market Research Report Added "Nuclear Medicine/Radiopharmaceuticals Market" to its database.
Albany, NY -- (SBWIRE) -- 02/24/2016 -- A new research report by Transparency Market Research (TMR) offers a comprehensive study of the global market for nuclear medicine/radiopharmaceuticals. The research study, titled "Nuclear Medicine/Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023," is available for sale on TMR's website.
The market study states that the rising prevalence of Parkinson's, cancer, Alzheimer's, several other forms of dementia, and cardiac failure is propelling the global nuclear medicine/radiopharmaceuticals market.
The report studies the global market for nuclear medicine/radiopharmaceuticals on the basis of the type of product and application. Based on product type, the market has been segmented into diagnostic products and therapeutic products in this study.
According to the report, the diagnostic products segment led the worldwide nuclear medicine/radiopharmaceuticals market in 2014.
Get Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5666
Further, the report classifies the diagnostic products segment into SPECT isotopes and PET isotopes and the therapeutic products segment into brachytherapy, alpha emitters, and beta emitters. The SPECT isotopes segment dominated the diagnostic products market in 2014, says the study.
Based on application, the report segments the global market for nuclear medicine/radiopharmaceuticals into neurology, cardiology, oncology, bone metastasis, thyroid, and endocrine tumors. In 2014, the cardiology segment held the largest share in the global nuclear medicine/radiopharmaceuticals market, states the report.
The study also evaluates the regional spread of the global market for nuclear medicine/radiopharmaceuticals. North America, Latin America, Europe, Asia Pacific, the Middle East and Africa, and the Rest of the World are the key regional markets for nuclear medicine/radiopharmaceuticals, states the research report.
North America dominated the global market in 2014 and was closely followed by Asia Pacific and Europe. The growing awareness among patients and medical professionals regarding the efficiency of nuclear medicine in treating various chronic diseases and cardiac disorders, coupled with the easy availability of radiopharmaceuticals, has boosted the North America nuclear medicine/radiopharmaceuticals market significantly in recent times.
Nowadays, the demand for nuclear medicine or radiopharmaceuticals is registering substantial growth in this region on account of the increasing prevalence of cancer as well as the rising incidence of cardiac arrest and other heart diseases in North America, notes the market study. Analysts at TMR, however, anticipate the Asia Pacific market for nuclear medicine/radiopharmaceuticals to register the highest growth rate over the forecast period.
Cardinal Health Inc., Eczacibasi-Monrol Nuclear Products, GE Healthcare, Bayer Healthcare AG, Mallinckrodt Plc, IBA Molecular Imaging, and Sigma Aldrich Corp. are the leading companies operating in the global market for radiopharmaceuticals/nuclear medicines, states the study. Other prominent market players mentioned in this report are Medtronic plc, Jubilant Pharma, Nordien Inc., and Siemens Healthcare.
Mr. Sudip S
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453